Dayvigo Cost in New York 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Lemborexant and Why Does Pricing Vary So Much?

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R signaling to reduce wake drive at bedtime. The FDA approved it in December 2019 under the brand name Dayvigo for treatment of insomnia disorder in adults [1]. In SUNRISE-1 (N=1,006), the 5 mg and 10 mg doses both produced statistically significant reductions in subjective sleep onset latency versus placebo at week 1, with benefits sustained through week 30 [2].

Pricing for any brand-name sleep drug in New York varies because the manufacturer sets a list price, pharmacy benefit managers (PBMs) negotiate rebates, state Medicaid sets its own reimbursement rates, and cash-pay aggregator programs (GoodRx, Cost Plus Drugs) apply their own discount contracts. Lemborexant is Schedule IV under the Controlled Substances Act [3], which means no automatic refills and mandatory DEA-compliant prescribing, adding a small dispensing overhead that generic insomnia drugs do not carry.

Orexin signaling research links hyperactive wake-promoting neurons to chronic insomnia, and the American Academy of Sleep Medicine (AASM) 2023 Clinical Practice Guideline conditionally recommends lemborexant for sleep-onset and sleep-maintenance insomnia in adults, stating: "We suggest the use of lemborexant for sleep onset and sleep maintenance insomnia in adults" [4]. That guideline endorsement has driven formulary pressure from patients and prescribers, which in turn influences what New York insurers choose to cover.

The 2026 Price Breakdown for New York Residents

The Eisai manufacturer list price for Dayvigo is $320 for a 30-tablet supply, regardless of strength (5 mg or 10 mg). That list price is the starting point. Very few patients actually pay it.

Cash-pay retail: The average cash price across New York retail pharmacies in 2026 sits at approximately $85 per month when discount card programs are applied [5]. GoodRx and RxSaver contracts with major chains (CVS, Walgreens, Rite Aid, independent NY pharmacies) bring the price into this range. Prices vary by ZIP code inside New York State, with New York City pharmacies often slightly higher than upstate locations due to operating costs, so checking multiple pharmacies or using a price-comparison tool before filling is worth the two-minute effort.

With commercial insurance: Patients with employer-sponsored or marketplace plans typically land a $40 to $80 copay after a successful prior authorization, depending on their plan's tier placement for Dayvigo. Step-edit requirements frequently demand documented failure of at least one formulary generic first, most often zolpidem (zolpidem tartrate, generic, ~$10/month) or trazodone [6].

Eisai patient support: Eisai's Dayvigo savings card reduces out-of-pocket cost to as low as $30 per month for eligible commercially insured patients [7]. Medicaid and Medicare beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback rules.

Compounded lemborexant: Licensed 503A compounding pharmacies in New York may prepare patient-specific formulations of lemborexant. Pricing at these pharmacies varies widely but can be substantially below retail brand-name cost. The legal framework governing this option is explained in a dedicated section below.

New York Medicaid Coverage for Dayvigo

New York Medicaid covers lemborexant (Dayvigo) with prior authorization (PA). That means the drug is on the preferred drug list but requires the prescriber to submit clinical documentation before the plan will pay.

To obtain PA approval through New York Medicaid Managed Care or fee-for-service, prescribers generally must document: (1) a formal diagnosis of insomnia disorder meeting DSM-5 criteria, (2) inadequate response or contraindication to at least one formulary-preferred generic hypnotic, and (3) absence of active substance use disorder that would preclude Schedule IV prescribing [8]. The specific managed care plan (Healthfirst, Fidelis, MetroPlus, Molina, etc.) may layer additional criteria on top of the state baseline.

New York Medicaid's Preferred Drug Program (PDP) is administered by the New York State Department of Health. Prescribers can check the current preferred drug list at ny.gov/health or through the eMedNY portal. If a PA is denied, New York Medicaid requires an appeal process that includes a fair hearing right, and a denial can be overturned with adequate clinical documentation.

The Sleep Foundation notes that chronic insomnia affects roughly 10 to 15 percent of the U.S. adult population, with higher prevalence in low-income groups who disproportionately depend on Medicaid [9]. Access through public insurance therefore carries real population health significance.

Commercial Insurance and Prior Authorization in New York

Most commercial insurance plans operating in New York place Dayvigo on Tier 3 or Tier 4 of the formulary, which means higher cost-sharing without prior authorization. Step therapy is the standard requirement, though New York's Step Therapy Reform Law (NY Insurance Law Section 4803) gives patients an expedited appeal right when step therapy is imposed, including the right to a step-therapy override if the required drug is contraindicated, has already been tried and failed, or would cause clinically significant harm [10].

Under that law, insurers must respond to a step-therapy override request within 72 hours (or 24 hours for urgent cases). A prescriber who documents that zolpidem is contraindicated in a given patient (e.g., history of parasomnia or complex sleep behaviors on zolpidem) or that the patient tried and failed a generic hypnotic can often obtain lemborexant coverage without going through the full step sequence.

Major commercial insurers active in New York that have covered Dayvigo with PA in recent plan years include UnitedHealthcare, Aetna, Cigna, Empire BlueCross BlueShield, and Oscar Health. Formularies change on January 1 each year, so verifying current coverage through your insurer's drug lookup tool before your appointment is the most reliable approach [11].

How the Eisai Savings Card Works in New York

The Eisai Dayvigo savings card (sometimes called the Dayvigo Co-pay Savings Program) is available to commercially insured patients in New York who meet eligibility criteria. The card reduces the monthly out-of-pocket cost to as little as $30 for a 30-day supply [7].

Eligibility requires that the patient:

• Has commercial (private) insurance that covers Dayvigo
• Is not enrolled in any federal or state government-funded health care program (Medicare, Medicaid, CHIP, TRICARE, or similar)
• Is a U.S. resident aged 18 or older
• Has a valid prescription from a licensed New York prescriber

The savings card is activated through Eisai's patient support line or the Dayvigo website. The maximum annual savings benefit and income thresholds are subject to change; patients should verify the current terms directly with Eisai at the time of enrollment. Patients who are uninsured and do not qualify for Medicaid may instead apply for Eisai's patient assistance program, which provides the drug at no cost to qualifying low-income individuals [12].

Compounded Lemborexant in New York: What Is and Is Not Legal

Compounded lemborexant is available through licensed 503A compounding pharmacies in New York, but several legal guardrails apply.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a patient-specific formulation of lemborexant when a licensed prescriber issues a valid prescription for an identified individual patient [13]. The FDA does not pre-approve 503A compounded formulations, and compounded lemborexant is not FDA-approved, which means it has not undergone the same clinical testing as the brand-name product.

New York's compounding oversight sits with the New York State Board of Pharmacy, which enforces USP Chapter 795 (non-sterile) standards and requires pharmacies to hold appropriate state licenses. Compounding is only permitted for a specific, identified patient. Anticipatory compounding (making batches without patient-specific prescriptions) for Schedule IV controlled substances like lemborexant faces additional DEA regulatory scrutiny.

The FDA's 2024 Compounding Policy Framework reinforces that compounded drugs should not be used as a routine alternative to FDA-approved drugs when the approved drug is available [14]. A prescriber in New York should document a legitimate clinical rationale for compounded lemborexant, such as a patient who requires a dose not commercially available (the approved doses are 5 mg and 10 mg) or who has a documented allergy to an excipient in the brand-name tablet.

The following decision framework summarizes the prescribing pathway for a New York clinician evaluating lemborexant access options:

1. Commercially insured patient: Submit PA, invoke NY Step Therapy Reform Law if needed, apply Eisai savings card if approved.
2. Medicaid patient: Submit PA with documented generic hypnotic failure, appeal if denied under fair hearing rights.
3. Uninsured patient with income qualification: Apply for Eisai patient assistance program.
4. Uninsured patient without income qualification: Use GoodRx or similar at cash price (~$85/month), or evaluate 503A compounded option if legitimate clinical rationale exists.
5. Patient with excipient allergy or off-label dose need: Refer to licensed 503A compounding pharmacy in New York with documented clinical rationale.

Telehealth Prescribing of Dayvigo in New York

Lemborexant can be prescribed via telehealth in New York. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 required an in-person evaluation before Schedule IV prescriptions could be issued via telemedicine, but a DEA special registration pathway and pandemic-era flexibilities have been extended through at least the end of 2025, allowing authorized telehealth providers to prescribe Schedule IV controlled substances including lemborexant without a prior in-person visit in many circumstances [15].

New York State additionally follows the guidance of the New York State Department of Health telehealth regulations, which permit audio-visual evaluations for prescription of controlled substances when the prescriber holds a valid New York license and the clinical documentation meets the standard of care for insomnia diagnosis. A sleep history, validated screening tool such as the Insomnia Severity Index (ISI), and documentation of prior treatment attempts support a defensible telehealth prescribing record [16].

HealthRX telehealth clinicians licensed in New York conduct synchronous video visits and can issue Dayvigo prescriptions to eligible patients when clinically appropriate, routing the prescription directly to the patient's pharmacy of choice.

Clinical Evidence Supporting the Cost

Cost matters more when efficacy is uncertain. For lemborexant, the SUNRISE-1 trial (N=1,006, randomized, double-blind, published in JAMA Network Open 2019) demonstrated that both 5 mg and 10 mg doses reduced mean subjective sleep onset latency by approximately 10 minutes versus placebo, with P<0.001 for both comparisons [2]. Sleep maintenance endpoints showed similar significance. SUNRISE-2 (N=949, 12-month data) confirmed that efficacy and the safety profile were sustained over one year without evidence of tolerance development [17].

Compared with suvorexant (Belsomra), the other approved DORA, a 2020 network meta-analysis published in The Lancet found lemborexant 10 mg ranked highest for sleep onset improvement among approved agents, including zolpidem and eszopiclone [18]. That comparative effectiveness evidence is relevant when arguing for formulary tier placement or PA approval in New York.

The risk of next-morning impairment is dose-dependent. The FDA label warns that driving ability may be impaired on the morning after taking 10 mg, and advises patients not to drive until they feel fully alert [1]. This is one reason some clinicians prefer starting at 5 mg, which is also the lower-cost option at most pharmacies since list price does not differ by strength.

What Affects Your Final Out-of-Pocket Cost in New York

Several variables determine what a New York patient actually pays:

Pharmacy selection. Independent pharmacies in New York sometimes offer lower cash prices than chains because their overhead differs and they can participate in different discount contracts. Calling ahead to compare prices between a CVS, a Costco pharmacy, and a local independent before filling is a straightforward way to find savings.

GoodRx vs. insurance. For some patients, using a GoodRx card at cash price (~$85/month) costs less than the Tier 3 copay on their insurance plan. Patients may use GoodRx in lieu of insurance for any given prescription fill; they cannot double-dip by using both simultaneously [19].

30-day vs. 90-day supply. Some New York insurers and mail-order pharmacies offer a lower per-unit cost for a 90-day supply. For a stable patient on 5 mg nightly, requesting a 90-day supply at first renewal can reduce annual spending by $60 to $120 depending on the plan.

Strength selection. Starting at 5 mg is both clinically supported and financially equivalent to 10 mg under Eisai's current pricing, since list price does not differ between strengths. If 5 mg achieves adequate sleep quality, staying at 5 mg avoids the next-morning impairment risk while holding cost flat.

Prior authorization timing. Delays in PA submission cost patients money when they pay cash while waiting for insurance approval. Submitting the PA before or at the time of the first prescription, rather than after the first cash-pay fill, avoids that gap.

Comparing Lemborexant to Other Insomnia Treatments on Cost

New York patients evaluating Dayvigo against alternatives should compare on both cost and clinical profile:

• Zolpidem (generic, 5 to 10 mg): ~$10/month cash. Shorter half-life, higher risk of complex sleep behaviors. FDA 2019 safety communication added boxed warning for complex sleep behaviors [20].
• Trazodone (generic, 50 to 100 mg off-label): ~$10/month cash. Sedating antidepressant used off-label for insomnia; not FDA-approved for this indication.
• Eszopiclone (generic Lunesta, 1 to 3 mg): ~$20, $30/month cash. Approved for sleep onset and maintenance; taste side effect common.
• Suvorexant (generic Belsomra, 10 to 20 mg): Generic launched in 2023; ~$40, $60/month cash in New York. Same DORA class as lemborexant.
• Doxepin (Silenor 3 to 6 mg or generic, low-dose): ~$20/month cash. Approved for sleep maintenance; not for sleep onset.

Lemborexant at ~$85/month occupies the premium end of the cash-pay market. For patients who have failed generics or who have a contraindication to benzodiazepine-receptor agonists, the AASM guideline supports lemborexant as an appropriate alternative [4]. For treatment-naive patients with no contraindications, the standard of care supports an initial generic trial first, which is also what New York Medicaid and most commercial plans require [8].

Prior Authorization Tips for New York Prescribers

Approval rates for Dayvigo PA requests improve when the submission includes all of the following:

1. DSM-5 insomnia disorder diagnosis with documented symptom duration (generally 3+ months, 3+ nights per week).
2. Objective or subjective evidence of impaired daytime functioning (ISI score, patient-reported fatigue, work impairment).
3. Documentation of at least one trial of a formulary-preferred generic, including the drug name, dose, duration, and reason for discontinuation or inadequate response.
4. Absence of uncontrolled substance use disorder.
5. Statement that behavioral interventions (CBT-I) were offered or are contraindicated due to access barriers.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment recommended by both the AASM and the American College of Physicians (ACP) [21]. Some New York insurers require documentation that CBT-I was offered before approving any pharmacotherapy for insomnia, including lemborexant. Acknowledging CBT-I in the PA submission, even when pharmacotherapy is still clinically justified, prevents automatic denials based on missing documentation.

If a PA is denied, New York's External Appeal Law allows patients to request an independent external review. For chronic conditions, the external reviewer must make a determination within 30 days; for urgent situations, within 72 hours [10].

Frequently Asked Questions